Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NESwc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkizTWM2OD1yLkCwNFQ2QCCwTR?= NHTFcm1USU6JRWK=
ES4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMECwOlU{KG6P MVvTRW5ITVJ?
ACHN NVfRUVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2WmlEPTB;MD6wNFA5QDdibl2= NXXaNnA6W0GQR1XS
KYSE-510 M2\lO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMECwPVc2KG6P MYHTRW5ITVJ?
EW-7 NH;JUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnj[2tJUUN3ME2wMlAxOjV6IH7N NF7yUo9USU6JRWK=
BFTC-905 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvodpJKSzVyPUCuNFA2OTVibl2= MXTTRW5ITVJ?
KE-37 NHPucnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;s[ZBlUUN3ME2wMlAxPTZzIH7N MlvPV2FPT0WU
SBC-5 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLRTWM2OD1yLkCwOVchdk1? M3TLeHNCVkeHUh?=
NKM-1 NFXVZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrUUGNKSzVyPUCuNFA4ODlibl2= NGTj[3hUSU6JRWK=
RH-1 NH21SY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL1TWM2OD1yLkCwO|E5KG6P M1jYWnNCVkeHUh?=
ALL-PO NIDhRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETNPJNKSzVyPUCuNFA5OyCwTR?= MXPTRW5ITVJ?
QIMR-WIL M2rMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDzRYlKSzVyPUCuNFA5QTRibl2= MVHTRW5ITVJ?
A375 NFzFe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6xbXpKSzVyPUCuNFA6QTVibl2= NEDPb5lUSU6JRWK=
SIG-M5 NELHZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEGwOEBvVQ>? MlvBV2FPT0WU
KGN M1LIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPCSm1KSzVyPUCuNFExQCCwTR?= NFH5UIZUSU6JRWK=
EW-13 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjINZJuUUN3ME2wMlAyOTJibl2= M3fnS3NCVkeHUh?=
NCI-SNU-1 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEG2JI5O NGHNdZFUSU6JRWK=
PSN1 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rwfGlEPTB;MD6wNVY2KG6P MVLTRW5ITVJ?
HUTU-80 M3rJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvuTXlXUUN3ME2wMlAyPjZibl2= MlHWV2FPT0WU
EW-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC1TWM2OD1yLkCyN{BvVQ>? NX3s[2RvW0GQR1XS
786-0 M3HPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEKzJI5O NHeyVIlUSU6JRWK=
ES1 M4\0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXvTWM2OD1yLkCyOlghdk1? NX3YOmdnW0GQR1XS
RKO M3POdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEK3PUBvVQ>? MWrTRW5ITVJ?
ESS-1 Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEK4OkBvVQ>? MmrZV2FPT0WU
SK-UT-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljMTWM2OD1yLkCyPVchdk1? NHvMS4VUSU6JRWK=
LB2241-RCC Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnwTWM2OD1yLkCzNVghdk1? M17PfnNCVkeHUh?=
CHL-1 NI\nN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPWTWM2OD1yLkCzNlQhdk1? NWW5eJRPW0GQR1XS
SW1783 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\MVpJ6UUN3ME2wMlA{OzZibl2= MXjTRW5ITVJ?
MEL-JUSO MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVroPYRCUUN3ME2wMlA{QTFibl2= Mmj6V2FPT0WU
HT-29 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMESxN{BvVQ>? M4WyRXNCVkeHUh?=
SNG-M MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu3b|dKSzVyPUCuNFQzPSCwTR?= M3jmd3NCVkeHUh?=
TE-15 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vVcmlEPTB;MD6wOFY1KG6P NGXMR2NUSU6JRWK=
HOS NGm1VWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMES4JI5O M4r6cnNCVkeHUh?=
BB65-RCC MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK3eHpqUUN3ME2wMlA2OTJibl2= MmjvV2FPT0WU
HCE-4 M{jOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PYcGlEPTB;MD6wOVI5KG6P MYjTRW5ITVJ?
MHH-ES-1 M4Hufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETsSoNKSzVyPUCuNFU{OSCwTR?= MnPkV2FPT0WU
RPMI-7951 NX;iNZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEW0NUBvVQ>? NHfxc25USU6JRWK=
IST-SL2 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDrSVhKSzVyPUCuNFU5PCCwTR?= NXHK[o5rW0GQR1XS
CMK M{TYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[2b2lEPTB;MD6wOVg3KG6P MVfTRW5ITVJ?
GR-ST Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT1TWM2OD1yLkC1PVUhdk1? NFr6dmJUSU6JRWK=
NALM-6 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwME[yNkBvVQ>? NWXjeWtrW0GQR1XS
RPMI-6666 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT2eoVKSzVyPUCuNFY2OiCwTR?= M3\B[HNCVkeHUh?=
LC-2-ad M4DhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL0TWM2OD1yLkC2OVMhdk1? M{[xenNCVkeHUh?=
ARH-77 NVnucGlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEexNUBvVQ>? MmPqV2FPT0WU
IST-MEL1 NXHaeG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TjbGlEPTB;MD6wO|I3KG6P NGjkVnJUSU6JRWK=
SW1710 NVH0NItKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILEPHJKSzVyPUCuNFc2OSCwTR?= NFzJNJBUSU6JRWK=
DEL M2jBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL0WYJ6UUN3ME2wMlA5QDdibl2= NHjTcJVUSU6JRWK=
AGS NEPId5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrP[nhKSzVyPUCuNFkxOiCwTR?= Ml2wV2FPT0WU
NCI-H2122 NH;hVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEm0OkBvVQ>? NUTQeGhSW0GQR1XS
HSC-4 NGL0S2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[xTWM2OD1yLkGwNkBvVQ>? NX\JOVNWW0GQR1XS
AM-38 NFzIdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfqeVRZUUN3ME2wMlEzOSCwTR?= NVyxTmxmW0GQR1XS
769-P M1zBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjIW3RKSzVyPUCuNVI{KG6P NHPTbZpUSU6JRWK=
RT-112 NEf4VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vZeWlEPTB;MD6xNlchdk1? MX;TRW5ITVJ?
MCF7 NIfDeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrXUZhKSzVyPUCuNVM3KG6P MWLTRW5ITVJ?
IGROV-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMUS1JI5O NHH2RXdUSU6JRWK=
OCI-AML2 M1n6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e3dGlEPTB;MD6xOFchdk1? Mn7DV2FPT0WU
NCI-H1299 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjleFVKSzVyPUCuNVU4KG6P NIHZWFdUSU6JRWK=
A431 NVq2Xo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP5TWM2OD1yLkG4N{BvVQ>? Mn;rV2FPT0WU
SW982 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDkTWM2OD1yLkKxN{BvVQ>? MX\TRW5ITVJ?
BB30-HNC NGLqfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LzdGlEPTB;MD6yN|Ehdk1? NWPnZlVMW0GQR1XS
ACN NHy5eXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3XTWM2OD1yLkK0OEBvVQ>? NIHVNo1USU6JRWK=
647-V MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzEZnJKSzVyPUCuNlQ5KG6P NGXRcFJUSU6JRWK=
SK-PN-DW NWrreFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnwTWM2OD1yLkK2OkBvVQ>? MXHTRW5ITVJ?
LCLC-97TM1 NGLFO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMk[3JI5O NIGwWmhUSU6JRWK=
LB1047-RCC NYDJUWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMk[5JI5O NGTmdYlUSU6JRWK=
A2780 NGW2WnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofBTWM2OD1yLkK3JI5O MnXEV2FPT0WU
C-33-A NITFZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfvTWM2OD1yLkK3N{BvVQ>? NYDkOlFVW0GQR1XS
NCI-H2228 M1XHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwM{G0JI5O MnXHV2FPT0WU
TE-5 NIC4[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4WxNGlEPTB;MD6zNVYhdk1? NVjzO|RjW0GQR1XS
HC-1 NYHjcHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwM{K3JI5O MVjTRW5ITVJ?
SK-MES-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjXTWM2OD1yLkOyPEBvVQ>? NVf2SIZiW0GQR1XS
NCI-H1355 NUj3O2FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HmSWlEPTB;MD6zPFEhdk1? MmHmV2FPT0WU
YKG-1 M3rlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK2[FRuUUN3ME2wMlQyQSCwTR?= NGfi[YtUSU6JRWK=
RS4-11 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj4bGc4UUN3ME2wMlQ{OyCwTR?= MmfuV2FPT0WU
Daoy MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OzOWlEPTB;MD60OVYhdk1? NVr3O4d6W0GQR1XS
A3-KAW MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPPVFROUUN3ME2wMlU2OSCwTR?= M1XjVHNCVkeHUh?=
SK-MEL-30 NX7IN3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwNUW0JI5O NV:3OHN1W0GQR1XS
U031 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LVdWlEPTB;MD61OlUhdk1? NEHiNmJUSU6JRWK=
SK-LMS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HLdmlEPTB;MD61O|ghdk1? NXzRe|JqW0GQR1XS
ES6 M4DGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrHdpMyUUN3ME2wMlU5PiCwTR?= M4L5[nNCVkeHUh?=
EoL-1-cell MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PVO2lEPTB;MD62NVYhdk1? MV;TRW5ITVJ?
NCI-H2009 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTzPJhsUUN3ME2wMlYyQSCwTR?= M1fxRnNCVkeHUh?=
A4-Fuk NWKxSXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlcoFKSzVyPUCuOlI3KG6P MVjTRW5ITVJ?
KYSE-270 NEm5[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu0ZlV6UUN3ME2wMlY{PCCwTR?= M4DXSnNCVkeHUh?=
SK-LU-1 M1X6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP5OZgzUUN3ME2wMlY2PSCwTR?= NIiyOHZUSU6JRWK=
SW872 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXPTWM2OD1yLke2OUBvVQ>? NU\pflN7W0GQR1XS
ES8 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq0UnNKSzVyPUCuO|ghdk1? MnPZV2FPT0WU
G-402 NEfDeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn4TWM2OD1yLke4OEBvVQ>? MVfTRW5ITVJ?
ATN-1 NEnDVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nMbmlEPTB;MD64NFchdk1? NFf6WpBUSU6JRWK=
DoTc2-4510 M3u5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfqTWM2OD1yLkmwNUBvVQ>? NWTaT21TW0GQR1XS
MES-SA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwOUC1JI5O MkPJV2FPT0WU
SF268 MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YOmRvUUN3ME2wMlkzPyCwTR?= MYrTRW5ITVJ?
SF539 NWPBZoEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PvbmlEPTB;MT6wNkBvVQ>? MWDTRW5ITVJ?
NB69 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DFemlEPTB;MT6wOUBvVQ>? NIexVplUSU6JRWK=
8505C MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XCcGlEPTB;MT6wOkBvVQ>? NVXHdFd1W0GQR1XS
CAL-12T NYft[5RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPHNWR1UUN3ME2xMlA5KG6P Ml33V2FPT0WU
BHY MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3TTWM2OD1zLkG0JI5O NEPoeXZUSU6JRWK=
LB647-SCLC NHLDeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3zTWM2OD1zLkG4JI5O NGnCVplUSU6JRWK=
CAL-62 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3XS2dKSzVyPUGuNlIhdk1? MV7TRW5ITVJ?
MEG-01 M2Ph[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\jTWM2OD1zLkK3JI5O NYXsTW9tW0GQR1XS
MG-63 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\LeJNKSzVyPUGuN|Mhdk1? M{CydnNCVkeHUh?=
SW620 NYfMTodGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOSoozUUN3ME2xMlM2KG6P MnnOV2FPT0WU
A388 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmydY1KSzVyPUGuN|Yhdk1? NF21R4tUSU6JRWK=
BCPAP MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LzTWlEPTB;MT60OUBvVQ>? MVfTRW5ITVJ?
P30-OHK NFW5WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwNE[gcm0> MVnTRW5ITVJ?
Ca9-22 NWmxTG5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwNUSgcm0> NY\3bmk6W0GQR1XS
VMRC-RCZ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSyc3JKSzVyPUGuOVQhdk1? M3jNTHNCVkeHUh?=
LOXIMVI Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJTWM2OD1zLk[gcm0> MkLYV2FPT0WU
L-540 NEHu[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLuV|A{UUN3ME2xMlYhdk1? M4WzSHNCVkeHUh?=
NTERA-S-cl-D1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwNkSgcm0> MUPTRW5ITVJ?
MFH-ino M3jxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsPW5KSzVyPUGuOlYhdk1? MX3TRW5ITVJ?
Calu-6 NYLyO5B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwN{Ogcm0> NGPkZmhUSU6JRWK=
HEL NGfo[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwN{mgcm0> NHTzUItUSU6JRWK=
CAL-33 NHPvbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D0TWlEPTB;MT64PUBvVQ>? MUHTRW5ITVJ?
HSC-3 M1jLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwOUGgcm0> MXLTRW5ITVJ?
KU812 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwOUGgcm0> MV;TRW5ITVJ?
EB2 M4H1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwMEGgcm0> NVnZWlVxW0GQR1XS
SR MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMUKgcm0> MXvTRW5ITVJ?
NCI-H2087 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwMUSgcm0> MV3TRW5ITVJ?
H4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfjbndKSzVyPUKuNVghdk1? M1XSfXNCVkeHUh?=
EW-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OzWmlEPTB;Mj6yNkBvVQ>? M4Pkb3NCVkeHUh?=
MC-IXC NFy0T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYTWM2OD1{LkK2JI5O MVjTRW5ITVJ?
NCI-H727 NIfwN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPUXYFOUUN3ME2yMlUyKG6P Mo\EV2FPT0WU
MRK-nu-1 NWfNbpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK2[m9KSzVyPUKuOVchdk1? Mn;QV2FPT0WU
COLO-668 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXaSGVKSzVyPUKuOlYhdk1? Ml3HV2FPT0WU
CGTH-W-1 NWLYOmpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hje2lEPTB;Mj63NkBvVQ>? NUDG[4JvW0GQR1XS
CHP-212 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEeybHhKSzVyPUKuO|Uhdk1? M4\GdnNCVkeHUh?=
GI-1 M1yzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwN{[gcm0> Mn35V2FPT0WU
HCC1806 M17QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwOUGgcm0> NE\TcmtUSU6JRWK=
HLE NF7ObVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzRTWM2OD1|IH7N M4foc3NCVkeHUh?=
HSC-2 NULNfZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwMEOgcm0> M2nMNHNCVkeHUh?=
DMS-273 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i1XGlEPTB;Mz6wO{BvVQ>? NVnySGRrW0GQR1XS
DU-4475 NG\GbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjDUJMxUUN3ME2zMlE1KG6P Ml7MV2FPT0WU
LXF-289 NIrYUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwM{Ggcm0> MXrTRW5ITVJ?
PANC-03-27 NIDKV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHJTWM2OD1|LkWxJI5O MXXTRW5ITVJ?
GAMG NXHLUGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwN{Sgcm0> NVPD[Ip1W0GQR1XS
NCI-H522 M16wZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnHTIhuUUN3ME20MlM1KG6P NXP3TZlDW0GQR1XS
SW626 M{fRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz0[HpKSzVyPUSuOFYhdk1? Mm[4V2FPT0WU
HT-144 NVzvephyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3p[JJKUUN3ME20MlkzKG6P NV3tdnRiW0GQR1XS
MEL-HO NVLye|A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPxb5hCUUN3ME21MlE3KG6P NFzsTnhUSU6JRWK=
BE-13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXPTWM2OD13LkKxJI5O M4nDWHNCVkeHUh?=
VA-ES-BJ M37KUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PtVGlEPTB;NT6yOkBvVQ>? NVv3VZBzW0GQR1XS
NCI-H441 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0XlVKSzVyPUWuOkBvVQ>? NVPke256W0GQR1XS
KP-4 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qyOWlEPTB;NT62NUBvVQ>? MULTRW5ITVJ?
LoVo NWrCXmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTKW5NtUUN3ME21MlcyKG6P MWHTRW5ITVJ?
HT-1080 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTVwOEOgcm0> M3n1ZnNCVkeHUh?=
GB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PhXmlEPTB;NT64OEBvVQ>? MnnCV2FPT0WU
IA-LM M3K2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTVwOUGgcm0> MUHTRW5ITVJ?
8-MG-BA M2\IRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPLTWM2OD13LkmzJI5O NFfNTIlUSU6JRWK=
SK-HEP-1 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDPcG5OUUN3ME22MlE1KG6P M4LJRXNCVkeHUh?=
697 NFLjTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixZZBZUUN3ME22MlI2KG6P NYrkRXk{W0GQR1XS
KYSE-450 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTZwM{Kgcm0> MUDTRW5ITVJ?
HCC2998 NUnVR4Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jFeGlEPTB;Nj6zOEBvVQ>? MkS2V2FPT0WU
HD-MY-Z MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTZwNkigcm0> NYPhWpZXW0GQR1XS
OS-RC-2 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfVPZZPUUN3ME22MlY5KG6P MYDTRW5ITVJ?
SF126 M3TD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfHTWM2OD15LkC1JI5O M1HEUXNCVkeHUh?=
Ca-Ski MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK0cotKSzVyPUeuNFkhdk1? NFq3VXJUSU6JRWK=
NCI-H358 NFrnb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrienFKSzVyPUeuNVYhdk1? NXvGTYRxW0GQR1XS
J82 M4H5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7hPHhKSzVyPUeuOFEhdk1? MXnTRW5ITVJ?
NCI-H2342 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS3[pVKSzVyPUeuOlMhdk1? M{XJT3NCVkeHUh?=
OVCAR-8 NH;BbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwOTDuUS=> M{[x[XNCVkeHUh?=
TE-8 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\xTWM2OD16IH7N M1PxeHNCVkeHUh?=
ETK-1 NUjIfVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESxT3dKSzVyPUiuNFghdk1? M4PNfnNCVkeHUh?=
HAL-01 M1f0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\oTWM2OD16LkKgcm0> MWrTRW5ITVJ?
KYSE-150 NFHjc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXPTWM2OD16LkS3JI5O MlLRV2FPT0WU
NCI-H810 NVjWWGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nHNGlEPTB;OD61OkBvVQ>? M3\BZ3NCVkeHUh?=
ONS-76 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\UTWM2OD16Lk[4JI5O MnHUV2FPT0WU
NMC-G1 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzP[XZKSzVyPUiuO|Yhdk1? MUPTRW5ITVJ?
C3A Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqzTWM2OD16Lki0JI5O MXXTRW5ITVJ?
PA-1 M{S2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OwWmlEPTB;OD65PUBvVQ>? M4OyZ3NCVkeHUh?=
SH-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvLfZJKSzVyPUmuNFIhdk1? MYfTRW5ITVJ?
EFO-27 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTlwMEWgcm0> NXPKWYlIW0GQR1XS
CAPAN-1 M1LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W1TmlEPTB;OT6yN{BvVQ>? NWHhTIpiW0GQR1XS
DU-145 NUfobVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTlwMkmgcm0> Mk\BV2FPT0WU
A101D M{HjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwM{egcm0> MmfkV2FPT0WU
ST486 NXn3UnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\yR4tXUUN3ME25MlQyKG6P MoizV2FPT0WU
NCI-H1437 NGTrNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVZ2lEPTB;OT60NkBvVQ>? MnHNV2FPT0WU
HGC-27 NIrUVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD17Lk[gcm0> MWrTRW5ITVJ?
8305C NYnyNG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nOemlEPTB;OT62OEBvVQ>? NGXQWo1USU6JRWK=
OCUB-M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TnR2lEPTB;MUCuNFMhdk1? NHPOT|RUSU6JRWK=
COLO-679 NEjPd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXUcYFxUUN3ME2xNE4xPyCwTR?= MVXTRW5ITVJ?
Detroit562 NVTjWHZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzSTWM2OD1zMD60NkBvVQ>? MWjTRW5ITVJ?
A204 NXHudJlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17UN2lEPTB;MUGuNVYhdk1? NGHFfGtUSU6JRWK=
NCI-H1734 NVL5U4NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfZSGNJUUN3ME2xNU4zQSCwTR?= M1zBbXNCVkeHUh?=
MC-CAR M161Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojBTWM2OD1zMT61PEBvVQ>? MkHXV2FPT0WU
NCI-H2170 NYDib|NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jacWlEPTB;MUGuPVchdk1? MWrTRW5ITVJ?
NCI-SNU-5 NGnXTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljvTWM2OD1zMj6xN{BvVQ>? NFO5WFVUSU6JRWK=
HCE-T NVyxb4wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjLW4d4UUN3ME2xNk41OiCwTR?= NWjpcHVOW0GQR1XS
KYSE-180 M1jSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkixJI5O MVvTRW5ITVJ?
C8166 M4nhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF|LkC4JI5O MV7TRW5ITVJ?
NCI-H460 M1nLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf3NGxGUUN3ME2xN{42PCCwTR?= NX6xbHpSW0GQR1XS
SNU-449 NH7iRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf1fVZKSzVyPUGzMlc4KG6P M2nxTXNCVkeHUh?=
MDA-MB-468 NWfDPJRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF2LkGyJI5O MluxV2FPT0WU
COR-L23 M2nEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\DTWM2OD1zND6xN{BvVQ>? NH21d4RUSU6JRWK=
CTV-1 NV3tN45XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjZTWM2OD1zND6xOEBvVQ>? NHSxOG5USU6JRWK=
BL-41 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPOWIxDUUN3ME2xOE4{PyCwTR?= NYTDZ|I6W0GQR1XS
IGR-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3POZ2lEPTB;MUSuOFIhdk1? M4jsXnNCVkeHUh?=
TK10 M1X3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPNTWM2OD1zND60PUBvVQ>? MWnTRW5ITVJ?
REH MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ewUWlEPTB;MUSuOVEhdk1? NXi1NJdmW0GQR1XS
LU-139 M4fJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrtR|hpUUN3ME2xOE42QSCwTR?= NVTUUYJjW0GQR1XS
KP-N-YS NFfwSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD2S2xxUUN3ME2xOE46PyCwTR?= NVXDTJhUW0GQR1XS
PANC-10-05 NGHNfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\lUId2UUN3ME2xOU4{QCCwTR?= NHTwT3lUSU6JRWK=
HL-60 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXYXFZKSzVyPUG1MlY6KG6P MnraV2FPT0WU
T84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrSTWM2OD1zNT65OkBvVQ>? M1fvNnNCVkeHUh?=
RPMI-8226 NVL0XJkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wTHRKSzVyPUG2MlAzKG6P MXzTRW5ITVJ?
UM-UC-3 NEfvbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK2TWM2OD1zNj6xOkBvVQ>? MWrTRW5ITVJ?
TE-10 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPTRnVUUUN3ME2xOk4zOSCwTR?= M3exfnNCVkeHUh?=
CAL-148 NVXVNpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF5LkKzJI5O MX7TRW5ITVJ?
BV-173 NFXkZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDxbIRiUUN3ME2xO{4zPyCwTR?= NHvKNnlUSU6JRWK=
Calu-3 M1H4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXEUlVUUUN3ME2xO{4zQSCwTR?= NF;oV2tUSU6JRWK=
RPMI-2650 M4PVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPBeGM3UUN3ME2xO{42QSCwTR?= MVLTRW5ITVJ?
MKN45 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXZe2dKSzVyPUG3Mlc{KG6P NInVXmZUSU6JRWK=
NUGC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P1WWlEPTB;MUiuN|Qhdk1? Mk\nV2FPT0WU
NCI-H520 M3KxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjKTWM2OD1zOD63O{BvVQ>? NIXibXZUSU6JRWK=
CCRF-CEM NF;GRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WzZ2lEPTB;MUiuPFUhdk1? NHK3TlhUSU6JRWK=
NCI-H2405 NXO5cWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF7LkGgcm0> M13IdnNCVkeHUh?=
ES7 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF7Lke2JI5O M37uPHNCVkeHUh?=
BPH-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnyTWM2OD1{MD6yPEBvVQ>? MYDTRW5ITVJ?
SAS NX35NoJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD1{MD61JI5O MXjTRW5ITVJ?
HuCCT1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1TWM2OD1{MD61PEBvVQ>? NVzTfXN1W0GQR1XS
LOUCY NVTFWm5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjvfI9HUUN3ME2yNE43PiCwTR?= NIjtcZVUSU6JRWK=
NCI-H292 M3nvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nERWlEPTB;MkCuO|khdk1? NUTVXFNQW0GQR1XS
G-361 NF;pSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvLTIJzUUN3ME2yNU4xPyCwTR?= MV\TRW5ITVJ?
M059J NYWyPXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXlTWM2OD1{MT6wPEBvVQ>? NXuyWHlkW0GQR1XS
NCI-H1651 M4PucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KzVmlEPTB;MkGuNVEhdk1? MYHTRW5ITVJ?
KALS-1 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37BU2lEPTB;MkGuN|khdk1? M3G0NnNCVkeHUh?=
DJM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PuW2lEPTB;MkGuOVkhdk1? NH\JbG9USU6JRWK=
AU565 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTpTWM2OD1{MT64N{BvVQ>? NYHXSWxnW0GQR1XS
HCC38 NG\xUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fxSGlEPTB;MkGuPVUhdk1? NYPnNZJQW0GQR1XS
U251 NXnlZWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjzT5JKSzVyPUKyMlI4KG6P M4XSU3NCVkeHUh?=
ABC-1 M1T3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ{Lk[1JI5O M3fWUXNCVkeHUh?=
SK-NEP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTSTWM2OD1{Mj65N{BvVQ>? NHzXfXZUSU6JRWK=
CESS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2OYRTUUN3ME2yN{4yQSCwTR?= MkLoV2FPT0WU
MIA-PaCa-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnOR3RKSzVyPUKzMlM3KG6P M3HHO3NCVkeHUh?=
SUP-T1 NEfDb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHPTWM2OD1{Mz60O{BvVQ>? NVP0fIRIW0GQR1XS
L-428 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jRPGlEPTB;MkOuOlIhdk1? NIPETJRUSU6JRWK=
SW954 M4H0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH20dXlKSzVyPUKzMlY5KG6P NHrrSopUSU6JRWK=
HO-1-N-1 NWLVcFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ|Lke3JI5O NI\jW|RUSU6JRWK=
CHP-126 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ2LkG0JI5O M3HKZnNCVkeHUh?=
HMV-II M2fsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\nTWM2OD1{ND6zOEBvVQ>? M4Pue3NCVkeHUh?=
NB10 NFnGd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ2LkO3JI5O MXHTRW5ITVJ?
A172 NXvmOldGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\JcmlEPTB;MkSuO|Ehdk1? MlLzV2FPT0WU
MONO-MAC-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPvWotKSzVyPUK0Mlg1KG6P NF7pS2ZUSU6JRWK=
NCI-H1650 NGLJcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD1{NT60JI5O MWfTRW5ITVJ?
NH-12 NVvJNVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml65TWM2OD1{NT61JI5O MlX4V2FPT0WU
ML-2 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HyZ2lEPTB;MkWuO|Qhdk1? Mn32V2FPT0WU
MZ2-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLyWZdKSzVyPUK2MlIzKG6P MXnTRW5ITVJ?
COLO-684 M1v5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HHbWlEPTB;Mk[uOFEhdk1? M33j[3NCVkeHUh?=
HuP-T4 NYi2ZZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzFU3ZqUUN3ME2yO{4{KG6P NVriV5J[W0GQR1XS
SW837 M1jQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ5Lk[yJI5O MmrlV2FPT0WU
MDA-MB-231 NIjEdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\wTWM2OD1{Nz63PEBvVQ>? MoC0V2FPT0WU
KYSE-140 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHftelNKSzVyPUK3MlkyKG6P NVrVbYtJW0GQR1XS
NOMO-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;y[5JKSzVyPUK4MlY5KG6P M1WwU3NCVkeHUh?=
GP5d NXHIdFN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ6LkeyJI5O MX3TRW5ITVJ?
COR-L105 NH2wUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLVTWM2OD1{OT60NkBvVQ>? NU\EWIJFW0GQR1XS
LS-411N NInKd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vRd2lEPTB;MkmuPFghdk1? NWi0R2RjW0GQR1XS
NY M1LJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDRZ2NDUUN3ME2zNE4yQCCwTR?= M3u1bnNCVkeHUh?=
NCI-H2030 M2PPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\mXGFbUUN3ME2zNE41PSCwTR?= MlvJV2FPT0WU
CCF-STTG1 NVrnWphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDVmlEPTB;M{GuOFIhdk1? NVfNRnZpW0GQR1XS
NCI-H1703 M3LTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fnSWlEPTB;M{GuO|ghdk1? NWPpXYdXW0GQR1XS
TUR Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M134V2lEPTB;M{KuNFMhdk1? NUfmeoc5W0GQR1XS
NOS-1 NV61WoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTN{LkS0JI5O MkS3V2FPT0WU
A2058 M1HEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrGTWM2OD1|Mj64N{BvVQ>? M3TjeXNCVkeHUh?=
LCLC-103H NH3UbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jzc2lEPTB;M{OuNlUhdk1? M1TsbHNCVkeHUh?=
NCI-H510A NEXwdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj4TWM2OD1|Mz6yO{BvVQ>? MXrTRW5ITVJ?
BC-1 M1j0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN|Lke3JI5O NXvsdo46W0GQR1XS
SK-CO-1 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXZTWM2OD1|ND6wNUBvVQ>? NFzCZmhUSU6JRWK=
A673 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3xWZVSUUN3ME2zOE4yPyCwTR?= MWDTRW5ITVJ?
VM-CUB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DtZ2lEPTB;M{SuOlkhdk1? M{XtUHNCVkeHUh?=
HH MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSxbFJGUUN3ME2zOU4xPiCwTR?= NEC1[IdUSU6JRWK=
CAL-27 NInxW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOyTWM2OD1|NT6xOkBvVQ>? M3;WTnNCVkeHUh?=
NEC8 NWT0V5BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[3TWM2OD1|NT6zO{BvVQ>? MmDNV2FPT0WU
BxPC-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfjWFVKSzVyPUO2MlkyKG6P NGLK[ZdUSU6JRWK=
SNB75 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN5LkK0JI5O NVn4OYlSW0GQR1XS
NB13 M3XJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvsTWM2OD1|OD6yN{BvVQ>? M2S4dHNCVkeHUh?=
SK-OV-3 M4jG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnjV2dDUUN3ME2zPE44PCCwTR?= MVvTRW5ITVJ?
ME-180 NVu5e|JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN6Lkigcm0> M4jnTnNCVkeHUh?=
JiyoyeP-2003 NUTjNHE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rKNmlEPTB;M{muN|ghdk1? MV;TRW5ITVJ?
LU-134-A Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3DTWM2OD12MD6wNkBvVQ>? MnqwV2FPT0WU
LS-123 NFjZdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYZ2VKSzVyPUSwMlI5KG6P M{fERnNCVkeHUh?=
COLO-800 NYGxW|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXRRoVKSzVyPUSwMlU3KG6P NEfXXG9USU6JRWK=
LB831-BLC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTRzLki1JI5O MVvTRW5ITVJ?
NCI-H747 NGTqRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBTWM2OD12Mj6yPEBvVQ>? NUi0RpkxW0GQR1XS
MZ7-mel M3vlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTR{Lk[2JI5O NH7lO2VUSU6JRWK=
GT3TKB NUnCRWZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vvTWlEPTB;NEKuO|Ihdk1? MUnTRW5ITVJ?
MOLT-16 NWjY[FNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CwcGlEPTB;NEOuNFUhdk1? NUj2VYZnW0GQR1XS
23132-87 NG\iO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHiPWhVUUN3ME20N{4xPSCwTR?= M1zmOnNCVkeHUh?=
PF-382 MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\tXZBKSzVyPUS0MlIzKG6P MWXTRW5ITVJ?
ES3 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[5TpV7UUN3ME20OE43KG6P MmnkV2FPT0WU
SW756 M1;wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR3LkG0JI5O MWTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 15 mg/mL (56.99 mM)
Water 14 mg/mL warmed (53.19 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
water warming
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID